Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases

被引:150
作者
De Groot, Jan Willem B. [1 ]
Rikhof, Bart [1 ]
Van Doom, Jaap [2 ]
Bilo, Henk J. G. [1 ,3 ]
Alleman, Maarten A. [1 ]
Honkoop, Aafke H. [1 ]
Van der Graaf, Winette T. A. [4 ]
机构
[1] Isala Klin, Dept Internal Med, NL-8025 AB Zwolle, Netherlands
[2] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Metab & Endocrine Dis, Utrecht, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
关键词
GROWTH-FACTOR-II; IGF-BINDING PROTEIN-3; C-ASSOCIATED OSTEOSCLEROSIS; MESSENGER RIBONUCLEIC-ACID; INSULIN-RECEPTOR ISOFORM; E-DOMAIN; COMPLEX-FORMATION; GENE-EXPRESSION; LABILE SUBUNIT; FACTOR SYSTEM;
D O I
10.1677/ERC-07-0161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This review focuses on the tumour types and symptoms associated with non-islet cell tumour-induced hypoglycaemia (NICTH) as well as the pathogenesis, diagnosis and treatment of this rare paraneoplastic phenomenon. In addition, we report two illustrative cases of patients suffering from NICTH caused by a solid fibrous tumour and a haemangiopericytoma respectively. In the first case, NICTH resolved following complete resection of the tumour, but in the second case the patient needed long-term treatment aimed at controlling hypoglycaemia because of non-resectable metastases. Many tumour types have been associated with NICTH. The crucial event in the development of NICTH seems to be overexpression of the IGF-II gene by the tumour. NICTH is characterised by recurrent fasting hypoglycaemia and is associated with the secretion of incompletely processed precursors of IGF-II ('big'-IGF-II) by the tumour. This induces dramatic secondary changes in the circulating levels of insulin, GH, IGF-I and IGF-binding proteins, resulting in an insulin-like hypoglycaemic activity of 'big'-IGF-II.
引用
收藏
页码:979 / 993
页数:15
相关论文
共 106 条
[1]   INSULIN-LIKE GROWTH FACTOR-II AND THE RIDDLE OF TUMOR-INDUCED HYPOGLYCEMIA [J].
AXELROD, L ;
RON, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (22) :1477-1479
[2]   The igf-1 receptor in cancer biology [J].
Baserga, R ;
Peruzzi, F ;
Reiss, K .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) :873-877
[3]   IMPAIRED FORMATION OF THE TERNARY INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX IN PATIENTS WITH HYPOGLYCEMIA DUE TO NONISLET CELL TUMORS [J].
BAXTER, RC ;
DAUGHADAY, WH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :696-702
[4]   The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia [J].
Baxter, RC .
HORMONE RESEARCH, 1996, 46 (4-5) :195-201
[5]   REGULATION OF THE INSULIN-LIKE GROWTH-FACTORS AND THEIR BINDING-PROTEINS BY GLUCOCORTICOID AND GROWTH-HORMONE IN NONISLET CELL TUMOR HYPOGLYCEMIA [J].
BAXTER, RC ;
HOLMAN, SR ;
CORBOULD, A ;
STRANKS, S ;
HO, PJ ;
BRAUND, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (09) :2700-2708
[6]   The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer [J].
Belfiore, Antonino .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) :671-686
[7]   Alterations of the 11p15 imprinted region and the IGFs system in a case of recurrent non-islet-cell tumour hypoglycaemia (NICTH). [J].
Bertherat, J ;
Logié, A ;
Gicquel, C ;
Mourriéras, F ;
Luton, JP ;
Le Bouc, Y .
CLINICAL ENDOCRINOLOGY, 2000, 53 (02) :213-220
[8]   Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6 [J].
Bond, JJ ;
Meka, S ;
Baxter, RC .
JOURNAL OF ENDOCRINOLOGY, 2000, 165 (02) :253-260
[9]   Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia [J].
Bourcigaux, N ;
Arnault-Ouary, G ;
Christol, R ;
Périn, L ;
Charbonnel, B ;
Le Bouc, Y .
CLINICAL THERAPEUTICS, 2005, 27 (02) :246-251
[10]   Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide [J].
Cebon, J. .
BRITISH JOURNAL OF CANCER, 2006, 95 (07) :853-861